Cerevance competitors

Barry Kappel is a Board Member at Sapience Therapeutics Inc and Founder, President and CEO at Sapience Therapeutics Inc and is based in New York City, New York. He has worked as Senior Consultant at Easton Associates, Senior Vice President Business Development at CONTRAFECT CORP, and Lab Manager and Senior Research Technician at Memorial Sloan - Kettering Cancer Center. Barry attended Emory University between 1994 and 1998 and Cornell between 2006 and 2007.

President and CEO of Expansion Therapeutics, a biotechnology company advancing therapies that target a range of serious diseases caused by RNA. Initially focused on expansion repeat disorders, a set of ~30 genetic diseases including myotonic dystrophy type 1 (DM1), the most frequent cause of adult onset muscular dystrophy. Proven track record in discovering and developing disease modifying small molecule drugs to treat genetically defined diseases. Co-founder and former Chief Scientific Officer of X4 Pharmaceuticals and co-inventor of its lead drug candidate, mavorixafor. Leadership roles in drug discovery and development at Lysosomal Therapeutics and co-inventor of LTI-291, a CNS drug in clinical development for Parkinson’s disease. Former Interim Head of Small Molecule Discovery at Genzyme and part of the executive team at AnorMED, which was acquired by Genzyme in 2006. Instrumental in the development of two FDA approved drugs: plerixafor, a CXCR4-targeted stem cell mobilizer, and ertapenem, an anti-bacterial. Ph.D. in synthetic organic chemistry from the University of British Columbia; completed postdoctoral fellowships at the University of Oxford and Ohio State University.

Michael Gilman, Ph.D. has served as a member of our board of directors since November 2013. Michael Gilman is currently Chairman and Chief Executive Officer for Arrakis Therapeutics, Inc., a role he has served in since 2016, and Chief Executive Officer and Director for Obsidian Therapeutics, Inc., a role he has served in since 2016. Previously, from 2014 to 2016 Michael Gilman was Founder and Chief Executive Officer of Padlock Therapeutics, Inc. Prior to Padlock, Michael Gilman served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec Inc. from 2012 to 2013. He joined Biogen Idec Inc. in 2012 following its acquisition of Stromedix, Inc., where he was Founder and Chief Executive Officer. Prior to founding Stromedix in 2006, from 1999 to 2005, Michael Gilman served in a variety of capacities, most recently as Executive Vice President, Research at Biogen Idec. From 1994 to 1999, Michael Gilman was at ARIAD Pharmaceuticals, Inc., where he was Executive Vice President and Chief Scientific Officer. From 1986 to 1994, Michael Gilman was on the scientific staff of Cold Spring Harbor Laboratory in New York. He also serves on the Board of Directors of X4 Pharmaceuticals, Inc. and the Scientific Advisory Board of FutuRx, an Israeli biotech accelerator. Michael Gilman was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute. He holds a Ph.D. in Biochemistry from University of California, Berkeley, and an S.B. in Life Sciences from Massachusetts Institute of Technology.